(CNN) — The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday. About two weeks ago, the FDA sent ...

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...

Moderna said Wednesday the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu vaccine candidate after holding a high-priority meeting with the company.

After the Food and Drug Administration initially declined to review Moderna's mRNA flu vaccine candidate, the drugmaker said Wednesday that the FDA reversed its decision and will allow Moderna to move ...